Clinical use of crizotinib for the treatment of non-small cell lung cancer

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJännePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• SodaMTakadaSTakeuchiKA mouse model for EML4-ALK-positive lung cancerProc Natl Acad Sci USA200810550198931989719064915
   PubMed Web of Science ®Google Scholar
• MorrisSWKirsteinMNValentineMBFusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphomaScience19942635151128112848122112
   PubMed Web of Science ®Google Scholar
• KrisMGJohnsonBEKwiatkowskiDJIdentification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC)J Clin Oncol201129Suppl Abstr CRA7506
   Google Scholar
• KwakELCamidgeDRClarkJClinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066J Clin Oncol200927 Suppl148s
   Google Scholar
• RodigSJMino-KenudsonMDacicSUnique clinicopathologic features characterize ALK rearranged lung adenocarcinoma in the western populationClin Cancer Res200915165216522319671850
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
   PubMed Web of Science ®Google Scholar
• ChiarleRVoenaCAmbrogioCPivaRInghiramiGThe anaplastic lymphoma kinase in the pathogenesis of cancerNat Rev Cancer200881112318097461
   PubMed Web of Science ®Google Scholar
• ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMol Cancer Ther2007612 Pt 13314332218089725
   PubMed Web of Science ®Google Scholar
• ZouHYLiQLeeJHAn orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsCancer Res20076794408441717483355
   PubMed Web of Science ®Google Scholar
• SasakiTKoivunenJOginoAA novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsCancer Res201171186051606021791641
   PubMed Web of Science ®Google Scholar
• TiseoMGelsominoFBoggianiDEGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutationsLung Cancer201171224124321168933
   PubMed Web of Science ®Google Scholar
• WallanderMLGeiersbachKBTrippSRLayfieldLJComparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: Implications for optimal clinical testingArch Pathol Lab Med2012136779680322742552
   PubMed Web of Science ®Google Scholar
• YangJZhangXSuJConcomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancerJ Clin Oncol201129Suppl 1510517
   Google Scholar
• CamidgeDRKonoSAFlaccoAOptimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatmentClin Cancer Res201016225581559021062932
   PubMed Web of Science ®Google Scholar
• ZhangXZhangSYangXFusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionMol Cancer2010918820624322
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYKwakELProgression-free survival (PFS) from a Phase I study of crizotinib (PF-02341066) in patients with ALKpositive non-small cell lung cancer (NSCLC)J Clin Oncol201129Suppl 152501
   Web of Science ®Google Scholar
• CrinoLCrinòLKimDInitial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): Profile 1005J Clin Oncol201129Suppl Abstr 7514
   PubMed Web of Science ®Google Scholar
• Xalkori [crizotinib, package insert]New York, NYPfizer Inc2011
   Google Scholar
• KimDWAhnMJShiYResults of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC)J Clin Oncol201230Suppl Abstr 7533
   Google Scholar
• CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a Phase 1studyLancet Oncol201213101011101922954507
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKPhase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALKpositive non-small cell lung cancer (NSCLC) (PROFILE 1007)Abstract LBA1 presented at the Annual Congress of the European Society for Medical OncologyVienna, AustriaSeptember 28–October 2, 2012
   Google Scholar
• ShawATSolomonBKenudsonMMCrizotinib and testing for ALKJ Natl Compr Canc Netw20119121335134122157554
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLSodaMMultiplex reverse transcription-PCR screening for EML4-ALK fusion transcriptsClin Cancer Res200814206618662418927303
   PubMed Web of Science ®Google Scholar
• NakajimaTKimuraHTakeuchiKTreatment of lung cancer with an ALK inhibitor after EML4-ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspirationJ Thorac Oncol20105122041204321102268
   PubMed Web of Science ®Google Scholar
• ChoiYLTakeuchiKSodaMIdentification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancerCancer Res200868134971497618593892
   PubMed Web of Science ®Google Scholar
• Mino-KenudsonMChirieacLRLawKA novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistryClin Cancer Res20101651561157120179225
   PubMed Web of Science ®Google Scholar
• MartelliMPSozziGHernandezLEML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissuesAm J Pathol2009174266167019147828
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancerClin Cancer Res20091593143314919383809
   PubMed Web of Science ®Google Scholar
• OuSHAzadaMDyJStiberJAAsymptomatic profound sinus bradycardia (heart rate ≤ 45) in non-small cell lung cancer patients treated with crizotinibJ Thorac Oncol20116122135213722088989
   PubMed Web of Science ®Google Scholar
• ChoiYLSodaMYamashita Y, et al; ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci USA2011108187535754021502504
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120120ra17
   PubMed Web of Science ®Google Scholar
• SasakiTOkudaKZhengWThe neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancersCancer Res20107024100381004321030459
   PubMed Web of Science ®Google Scholar
• TanizakiJOkamotoIOkabeTActivation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancerClin Cancer Res201218226219622622843788
   PubMed Web of Science ®Google Scholar
• GorreMEMohammedMEllwoodKClinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplificationScience2001293553187688011423618
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
   PubMed Web of Science ®Google Scholar
• KwakELSordellaRBellDWIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci USA2005102217665767015897464
   PubMed Web of Science ®Google Scholar
• ZhangJYangPLGrayNSTargeting cancer with small molecule kinase inhibitorsNat Rev Cancer200991283919104514
   PubMed Web of Science ®Google Scholar
• LovlyCMHeuckmannJMde StanchinaEInsights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitorsCancer Res201171144920493121613408
   PubMed Web of Science ®Google Scholar
• SakamotoHTsukaguchiTHiroshimaSCH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutantCancer Cell201119567969021575866
   PubMed Web of Science ®Google Scholar
• ChenZSasakiTTanXInhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogeneCancer Res201070239827983620952506
   PubMed Web of Science ®Google Scholar
• NeckersLWorkmanPHsp90 molecular chaperone inhibitors: are we there yet?Clin Cancer Res2012181647622215907
   PubMed Web of Science ®Google Scholar
• GossGDThe GALAXY trial (NCT01348126): a randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIB or IV NSCLCJ Clin Oncol201230Suppl 15TPS7613
   Web of Science ®Google Scholar
• SequistLVGettingerSSenzerNNActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancerJ Clin Oncol201028334953496020940188
   PubMed Web of Science ®Google Scholar
• WongKKoczywasMGoldmanJWAn open-label Phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC)J Clin Oncol201129Suppl Abstr 7500
   Google Scholar
• RobertsPJUsaryJEDarrDBCombined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer modelsClin Cancer Res201218195290530322872574
   PubMed Web of Science ®Google Scholar
• CharestALaneKMcMahonKFusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6) (q21q21)Genes Chromosomes Cancer2003371587112661006
   PubMed Web of Science ®Google Scholar
• GuTLDengXHuangFSurvey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinomaPLoS One201161e1564021253578
   PubMed Web of Science ®Google Scholar
• SharmaSBirchmeierCNikawaJO’NeillKRodgersLWiglerMCharacterization of the ros1-gene products expressed in human glioblastoma cell linesOncogene Res198952911002691958
   PubMedGoogle Scholar
• RikovaKGuoAZengQGlobal survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancerCell200713161190120318083107
   PubMed Web of Science ®Google Scholar
• RimkunasVMCrosbyKELiDAnalysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusionClin Cancer Res201218164449445722661537
   PubMed Web of Science ®Google Scholar
• TakeuchiKSodaMTogashiYRET, ROS1 and ALK fusions in lung cancerNat Med201218337838122327623
   PubMed Web of Science ®Google Scholar
• BergethonKShawATOuSHROS1 rearrangements define a unique molecular class of lung cancersJ Clin Oncol201230886387022215748
   PubMed Web of Science ®Google Scholar
• YasudaHPreclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancerJ Thorac Oncol2012771086109022617245
   PubMed Web of Science ®Google Scholar
• McDermottUGenomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitorsCancer Res20086893389339518451166
   PubMed Web of Science ®Google Scholar
• ShawATClinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangementASCO Meeting Abstracts20123015_suppl7508
   Google Scholar
• FengYThiagarajanPSMaPCMET signaling: novel targeted inhibition and its clinical development in lung cancerJ Thorac Oncol20127245946722237263
   PubMed Web of Science ®Google Scholar
• Ma PC, et al. c-Met: structure, functions and potential for therapeutic inhibitionCancer Metastasis Rev200322430932512884908
   PubMed Web of Science ®Google Scholar
• ChenYTClinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatmentJ Thorac Oncol20116122027203522052229
   PubMed Web of Science ®Google Scholar
• DziadziuszkoRCorrelation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancerJ Thorac Oncol20127234034722237262
   PubMed Web of Science ®Google Scholar
• ParkSHigh MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patientsHistol Histopathol201227219720722207554
   PubMed Web of Science ®Google Scholar
• VincentMDBiomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASCurr Oncol201219Suppl 1S33S4422787409
   PubMed Web of Science ®Google Scholar
• OuSHActivity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplificationJ Thorac Oncol20116594294621623265
   PubMed Web of Science ®Google Scholar
• ChiASClinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastomaASCO Meeting Abstracts20122915_suppl2072
   Google Scholar
• LennerzJKMET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinibJ Clin Oncol201129364803481022042947
   PubMed Web of Science ®Google Scholar